THE SOUTH FLORIDA 
 Stock & Bond Club
 Proudly presents:
 -----------------------------



DESCRIPTION

The South Florida Stock & Bond Club Proudly Presents Payment Data Systems Inc. (NASDAQ: PYDS) at the Renaissance Boca Raton Hotel
on Monday, May 21, 2018 

Event Information: Our gracious host is sponsoring an OPEN BAR for the cocktail hourwhich will take place outside at the covered rotunda by the pool with a delicious Antipasto complete with Assorted Cured Meats, Cheese, Grilled Vegetables, Bread and Flatbread Crackers. Dinner entrees include your choice of 8 oz. Filet Mignon with a Blue Cheese Crusted Port Wine Reduction, Panko Crusted Salmon with a Dijon Cream Sauce or Penne Pasta Primavera with a mix of vegetables with Roasted garlic Pomodoro. 

In order to ensure your entrée selection and seat it is crucial that you register through Eventbrite or email Scott Gordon directly at scottg@coreir.com. 


About Payment Data Systems Inc. 

Payment Data Systems, Inc. (NASDAQ:PYDS), a leading integrated payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus, and card issuers. The Company operates credit, debit/prepaid and ACH payment processing platforms to deliver convenient, world-class payment solutions and service to their clients. The strength of the Company lies in its ability to provide tailored solutions for card issuance, payment acceptance, and bill payments as well as its unique technology in the prepaid sector. Payment Data is headquartered in San Antonio, Texas, and has offices in New York, New York; Long Beach, California; St. Augustine, Florida and Nashville, Tennessee. Websites: www.paymentdata.com, www.singularpayments.com, www.payfacinabox.com, www.akimbocard.com, and www.ficentive.com. Find us on Facebook®.

Corporate Highlights: 
Established provider of ACH and credit card payment processing in niche verticals. Q4’17 and Q1 2018 credit card transaction processing volumes were the highest in the history of the company. Record last quarter – annual revenue run rate of $25 million (vs. $12 mill for FY 2016) 
Recurring revenues and attractive margins
(% gross margins, % EBTIDA margins) 
Blue chip customers for prepaid phone cards such as Eli Lily,
Merk and Pfizer. 
Investing in innovation (One of the first prepaid card integrated with
Apple Pay, Samsung Pay, Google Wallet) 
Strong balance sheet, clean capital structure,
$40 million NOL. No Debt

ABOUT YOUR PRESENTER
Louis Hoch

Co-founder, Vice-Chairman, President, Chief Executive Officer,
​Chief Operating Officer

Mr. Hoch has more than 25 years of management experience 20 of which at a senior executive level of public companies. Mr. Hoch is an expert in payment processing and service bureau operations. In additions to his duties as the CEO of FiCentive, Mr. Hoch remains responsible for all operations and strategy for Payment Data Systems, Inc. in his role as Vice-Chairman, President and COO and co-founder. Mr. Hoch previously co-founded Billserv, Inc., the industry leader in Electronic Bill Presentment and Payment, where he was the company’s President and COO. Billserv reached a peak market cap of over 500 million while on NASDAQ national market exchange. Billserv is now owned by American Express. Mr. Hoch has held various key management positions with U.S. Long Distance (NASDAQ:USLD), Billing Concepts (NASDAQ:BILL) and Andersen Consulting (NYSE:ACN). Mr. Hoch holds a BBA in computer information systems and a MBA in international business management, both from Our Lady of the Lake University. Mr. Hoch is currently a director on the advisory board for Our Lady of the Lake University Business School. He is also a past executive lecturer in the school’s weekend MBA program. He is a past board member of San Antonio Children’s Museum.

Mr. Hoch holds inventor status on U.S. Patent 7,021,530 “System and method for managing and processing stored-value cards and bill payment therefrom”. He has other published patent pending applications which are all related to the payment processing industry.

PLEASE NOTE COCKTAILS BEGIN AT 5:30pm and will take place in the OUTDOOR ROTUNDA. Please follow the signage for the Stock & Bond Club Meeting.

6:30 pm Dinner & Company Presentation

Directions below

Business attire required. Please RSVP
to this e-mail by Friday, May 18, 2018.

South Florida Stock & Bond Club

http://www.stockandbondclub.com

Looking forward to a wonderful evening and to seeing you all then

PLEASE SAVE THE DATE: **Monday, June 18, 2018** FORTRESS BIOTECH (NASDAQ: FBIO) will be hosting our next meeting. More details to follow!

_____________________________

Scott Gordon, President

The location of the Renaissance Boca Raton Hotel
is 2000 NW 19th Street Boca Raton, Florida 33431
Telephone: 561-368-5252


Driving Directions: From I-95 to exit 45 (Glades Road. West) to 1st traffic light (Renaissance Way). Turn left on Renaissance Way and go one block to NW 19th St, Turn left on NW 19th Street. Hotel is on right.

Please note that every attempt has been made to accommodate your electronic RSVP and entrée ordering ease. If you require special meal preparation or any assistance, please email Scott Gordon at scottg@coreir.com or call him at 631 703 4900.

___________________________

 


 


​​_________________________

5:30 pm cocktails - 6:30 pm Dinner & Presentation.

The meeting will be held at the
Boca Raton Country Club.

_________________________________________



















New members are welcome for our 2018 season!

 Please fill out an application at the meeting
and bring $75.00 cash or check.


​​
 Made
payable to: 
South Florida Stock & Bond Club.
____
_____________

You may also mail your payment to:

South Florida Stock & Bond Club
6278 N. Federal Highway #195
Fort Lauderdale FL 33308-1916
Phone: (954) 719-1151







































 
























































presenting on 2018!


PAST PRESENTERS

Sigma Labs Inc. (NASDAQ: SGLB) atThe South Florida Stock & Bond Club Proudly at the Boca Raton Country Club 
​on Thursday, April 26, 2018.
 
About Sigma Labs, Inc. Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance (IPQA) software for commercial firms worldwide seeking productive solutions for advanced manufacturing. The company is involved in a range of activities in which it seeks to also commercialize its technologies and products in the aerospace and defense, bio-medical manufacturing; automotive manufacturing, and other markets. For more information please visit us at www.sigmalabsinc.com 

Sigma Labs is at the cusp of burgeoning demand in the 3D printing & design industry. Use of 3D technology is surging. Sales reached $1 billion in 2007, jumped to nearly $5.2 billion in 2015 and are expected to hit $26.5 billion by 2021.

 Problems that exist within the industry as whole right now involve no end-to-end solutions. President Trump has been increasing defense spending with efficiency. Aerospace & Defense companies are commercializing 3D metals but still have issues. Expensive aerospace parts need efficient production and high yield. The industry is seeking an holistic Value-Chain with part to part repeatability. Sigma is focused on being a world class provider of advanced manufacturing technology, offering an integrated commercialized solution which addresses the entire value-chain.

Sigma’s PrintRite3D® Quality Assurance Software product bridges prototype to production gap. Some of Sigma Lab’s clients include: Pratt & Whitney, Woodward, GE Aviation, Honeywell (DARPA program), Aerojet, and Boeing.

Recent News: April 2018 - Sigma Labs Announces Closing Of $1.0 Million. Private Placement Financing.

March 2018 - Sigma Labs Signs Cooperative Agreement With The National Institute Of Standards And Technology To Assess Improving Production Yields Of Metal Additive Manufacturing Using Printrite3d® Technology

March 2018 - Sigma Labs Releases Version 3.0.2 Of Its Printrite3d INSPECT® Software Enabling Rapid Process Qualification, Increased Production Yields And Faster Product To Market Times

January 2018 - Sigma Labs Awarded Contract With Laser Zentrum Nord Gmbh For Printrite 3D® To Certify Its IPQA® Methodology For Serial Production

December 2017: Sigma Labs Awarded Contract With Laser Zentrum Nord Gmbh For Printrite 3d® To Certify Its Ipqa® Methodology For Serial Production

November 2017: Sigma Labs And 3dsim Release Simulation Capability To Model Thermal Sensors For Metal Additive Manufacturing Processes
 

ABOUT YOUR PRESENTER: John Rice, Interim CEO and Chairman of the Board of Directors

John Rice has extensive experience in business operations. In 1990, Mr. Rice founded ASiQ, LLC, a firm specializing in operations management services ranging from launching successful startups and executing business turnarounds to financings, crisis management and the repositioning of enterprises for sale at optimum market prices. Mr. Rice presently serves as ASiQ’s CEO and President. He also served as CEO of Coca-Cola Bottling Company of Santa Fe, a client of ASiQ’s, from 2009 to 2015. From 2010 to 2012, Mr. Rice served as Director and Contracts Officer of Detector Networks International. Mr. Rice frequently lectures on breakout growth strategies, crisis management, corporate turnarounds, venture capital, 
and financial structuring and strategies. He has also served on a number 
of boards. Since 2005, Mr. Rice has served as Director of New Mexico Angels, Inc., a New Mexico based group of accredited individual angel investors. Since 2016, Mr. Rice has served as Director of Akal Security, Inc. He was also a Director of Detector Networks International from 2010-2012, where he successfully negotiated business turnaround for the company. 
Mr. Rice is an honors graduate of Harvard College.


Lilis Energy, Inc., (NYSE American: LLEX) presented at The South Florida Stock & Bond Club at the Renaissance Boca Raton Hotel on Wednesday, April 18, 2018. About Lilis Energy, Inc. Lilis Energy, Inc. is a San Antonio-based independent oil and gas exploration and production company that operates in the Permian’s Delaware Basin, considered amongst the leading resource plays in North America. Lilis’ current total net acreage in the Permian Basin is over 19,000 acres. Lilis Energy's near-term E&P focus is to grow current reserves and production and pursue strategic acquisitions in its core areas. For more information, please visit www.lilisenergy.com.

Recent Developments: March 2018 - Lilis Energy announces Grizzly #2H And Lion #3H IP24 Rates - The Grizzly #2H and the Lion #3H are Lilis's ninth and tenth successful operating horizontal Wolfcamp wells in the Permian's Delaware Basin and both continue the trend of Lilis producing some of the highest IP rates based on an IP per 1,000 ft. in the basin.

March 2018 - Lilis Energy announces new midstream solution operational and reported current production exceeds 5,000 Boepd and growing as the midstream system reaches maximum efficiency and additional wells currently in flowback and completion stage achieve peak production. March 2018 - Lilis Energy announces the closing of Delaware Basin acquisition net acreage position increases to over 19,000 acres - Acquired approximately 2,798 net acres in southeastern New Mexico in the Delaware Basin for approximately $65 million.

March 2018 - Lilis Energy provides operational update and review of fourth quarter and fiscal year 2017 operations - Average 2017 daily production increased 350% year over year to 1,575 Boepd -- Total production during 2017 was 575,229 net Boe, an increase of 350% year over year -- Average 4Q17 daily production increased 206% to 1,925 Boepd from 4Q16 -- Net Acreage increased by over 100% year over year to ~16,000 net acres, with ~8,800 net acres added in 2017 -- Increased proved reserves by over 950% during 2017.

February 2018 - Lilis Energy announces approval of share repurchase program by lenders and preferred equity holder authorizing the repurchase of up to $10 million of the Company's common stock in the open market. January 2018 - Lilis Energy announces private placement of $100 million of preferred stock. 

January 2018 - Lilis Energy announces the closing of new 3 year, $50 million first lien credit facility with Riverstone Credit Partners, L.P. The new credit facility will have additional availability of up to an additional $30 million which was uncommitted at closing.

ABOUT YOUR PRESENTER: Ron Ormand, Executive Chairman of the Board of Directors. Mr. Ormand, joined Lilis’s Board as a Director in March of 2015 and brings more than 33 years’ experience as a senior executive and investment banker in the energy sector to his role as Executive Chairman. Mr. Ormand’s background includes extensive financing expertise and merger and acquisition acumen in the oil and gas industry. During his career,Mr. Ormand has completed more than $25 billion of capital markets and financial advisory transactions. In addition, Mr. Ormand has substantial experience in the acquisition and restructuring of distressed energy companies, which will provide a significant benefit to
Lilis’s growth strategy. Mr. Ormand most recently served as Senior Managing Director of Investment Banking Group at FBR & Co., after the company acquired MLV & Co. in September of 2015, where he had held the posts of Chairman of the Board and Head of Investment Banking. Prior to that time, Mr. Ormand was a senior executive for four and a half years at Magnum Hunter Resources Corporation, an E&P company engaged in acquisition and development of unconventional resource plays in oil and gas and midstream gathering and transportation. Mr. Ormand was part of the initial senior management team that grew MHR from approximately $35 million enterprise value when he joined the Company in 2009 to more than $2.5 billion enterprise value by late 2013, when Mr. Ormand ​departed MHR. Mr. Ormand also served in several senior management positions, including Executive Vice President and Chief Financial Officer, and was a member of MHR’s Board of Directors. Mr. Ormand’s career also includes serving as Managing Director and Group Head of U.S. Oil and Gas Investment Banking at CIBC World Markets and Oppenheimer (1988-2004); Head of North American Oil and Gas Investment Banking at West LB A.G. (2005-2007), and President, CFO and Director of Tremisis Energy Acquisition Corp. II (2007-2009). Mr. Ormand holds a B.A. in Economics, and an MBA in Finance and Accounting, from UCLA, and studied Economics at Cambridge University, England.

Fennec Pharmaceuticals, Inc., (NASDAQ: FENC) presented at the Boca Raton Country Club on Thursday, March 15, 2018. 
About Fennec Pharmaceuticals, Inc. Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutical company focused on the development of PEDMARK (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients. STS has received Orphan Drug Designation in the US in this setting. Fennec has completed two pediatric phase 3 studies and plans to file for ​approval of PEDMARKTM in 2018. Recent Developments: · December 2017 - Fennec Announces Closing Of Public Offering -
The total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) was $21,153,270.
· During the third quarter, the Company announced positive results from
its Phase 3 SIOPEL 6 Study, which met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing loss without any evidence of tumor protection in patients with Standard Risk Hepatoblastoma (SR-HB)
· Company plans to pursue regulatory approvals with FDA and EU in 2018
For more information please visit: http://fennecpharma.com 
ABOUT YOUR PRESENTER: ROSTISLAV RAYKOV, CEO:  Mr. Raykov has served as a director of Fennec Pharma and Chief Executive Officer since July 2009. Mr. Raykov was a co-founder and portfolio manager for Alchem Investment Partners, an event driven hedge fund. Mr. Raykov also worked as a portfolio manager for Purchase Associates, an event driven hedge fund owned by John Levin & Co. He began his career as a financial analyst in the natural resources group at Bear Stearns. Mr. Raykov graduated from University of North Carolina at Chapel Hill, where he earned a Bachelor of Science degree in business administration.

CHF Solutions Inc., (NASDAQ: CHFS) presented at The South Florida Stock & Bond clubat the Boca Raton Country Club on ​Tuesday, February 27, 2018. About CHF Solutions: Formerly Sunshine Heart, CHF Solutions, Inc. (NASDAQ:CHFS) is an Eden Prairie, MN early-stage medical device company focused on commercializing the Aquadex FlexFlow Aquapheresis System. The Aquadex FlexFlow Aquapheresis System, is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF is headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

Recent Developments: 
· February 2018 - CHF Solutions, Inc. strengthens sales force with the appointment of Richard E. Roberts as its Senior Director of U.S. Sales, who will lead the US sales force for the company’s Aquadex FlexFlow System. 
· January 2018 - CHF Solutions, Inc. commences in-house manufacturing of aquadex flexflow console and blood circuits. 
· January 2018 – CHF Solutions, Inc. appoints Vitaliy Epshteyn Vice President of Operations and Engineering 
· December 2017 - CHF Solutions signs international distribution and services agreement with Singapore-based TRANSMEDIC Pte Ltd.
· November 2017 - CHF Solutions, Inc. announced the closing of $18.0 Million underwritten Public Offering of Series F convertible preferred stock, together with warrants, for gross proceeds of $18.0 million.
Q3 results for the period ending September 30, 2017:
· CHF Solutions, Inc. announced 21% revenue growth which included the following highlights:
· Revenue for third quarter ended September 30, 2017 increased 21% compared to the same period in 2016 on a proforma basis.
· Hired and trained 6 additional experienced sales professionals and increased the US sales team to 10 territories, up from 4 territories in Q2.
· Initiated international distribution by signing a distribution agreement with APC Cardiovascular Ltd., a distributor based in the United Kingdom.
· Held a scientific advisory board meeting with 6 key physician opinion leaders that provided guidance on protocol design for a mechanistic study and a registry study expected to begin in early 2018.
· Transition of Aquadex FlexFlow System manufacturing from Baxter to in-house operations going as planned and on schedule. In-house manufacturing expected to commence in the fourth quarter of 2017.
· Reduced operating expenses by 31% and operating cash utilization by 35% from same quarter last year.
· Subsequent to quarter end, received NASDAQ notification that Company is in compliance with minimum bid price requirements and the listing matter has been closed. For more information please visit: http://ir.sunshineheart.com . 

ABOUT YOUR PRESENTER: Claudia Napal Drayton, Chief Financial Officer. Claudia Drayton joined CHF Solutions in January of 2015 as Chief Financial Officer. Ms. Drayton spent the prior 15 years at Medtronic, Inc., a global leader in the medical device industry. During her tenure, she held multiple senior managerial finance positions in Medtronic’s Corporate Finance organization and its Cardiac Rhythm Management division, culminating with a two year assignment in Europe serving as Chief Financial Officer of the Peripheral Vascular Business and most recently, as Chief Financial Officer and Senior Finance Director of the Integrated Health Solutions business. In these capacities her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, business integrations and implementation of financial best practices.

Before Medtronic, Ms. Drayton was an Audit and Business Advisory Manager at Arthur Andersen for seven years. She is a certified public accountant, graduated with a BS in Accounting from the University of Mary Hardin-Baylor and holds an MBA from the University of Minnesota’s Carlson School of Management​. 


Altimmune, Inc. (NASDAQ:ALT) presented at the Boca Raton Country Club on Tuesday, December 12, 2017.
​About Altimmune - Immunotherapeutics for a Better Tomorrow: Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.

Recent Corporate Highlights: Initiated a proof-of-concept Phase 2 Flu vaccine clinical trial with the Company’s first-in-class NasoVAX™ vaccine, with initial data expected in 1Q-2018. Completed enrollment in the Company’s HepTcell™ immunotherapeutic Phase 1 clinical trial against hepatitis B, with topline data expected in 4Q-2017. Remained on track to initiate a BARDA-funded Phase 1 trial with NasoShield™, a next-generation intranasal, single-dose, anthrax vaccine in the first quarter of 2018, with topline data anticipated in the second quarter of 2018.
Remained on track to initiate a key pre-clinical bridging study with SparVax-L™, a lyophilized anthrax vaccine, in the fourth quarter. The study is fully-funded by NIAID. Closed a Series B preferred stock offering, raising approximately $13.0 million in net proceeds

ABOUT YOUR PRESENTER. Bill Enright - Chief Executive Officer. Mr. Enright currently serves as our President and CEO and is a member of our board of directors. He was first elected to our board of directors in June 2008. Mr. Enright brings more than 25 years of experience in a variety of positions within the life science and biotech industries. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. (NASDAQ: GNVC) with increasing responsibilities culminating in the Head of Business Development. Mr. Enright was responsible for helping to build GenVec’s vaccine business including generating approximately $140 million of funding for vaccine-related initiatives and moving four vaccines into clinical development. Prior to GenVec, Mr. Enright was a self employed consultant providing business development and strategic marketing services to academic institutions and a number of small to mid-size life science companies. Prior to becoming a consultant, and after spending several years as a bench scientist at SUNY at Buffalo, Mr. Enright spent 12 years with Life Technologies, Inc., working in various licensing, business management, manufacturing and research roles. Mr. Enright received a Master of Arts in Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.


Piedmont Lithium Ltd (ASX-PLL, NASDAQ- INTERNATIONAL-PLLLY) presented at The Stock & Bond CLub November 30, 2017. The company holds a 100% interest in the Piedmont Lithium Project ("Project") which is located within the world-class Carolina Tin-Spodumene Belt ("TSB"), and along trend to the Hallman Beam and Kings Mountain mines, historically providing most of the western world's lithium between 1950 and 1990. The TSB is one of the premier localities in the world to be exploring for lithium pegmatites given its history of lithium bearing spodumene mining, favorable geology and ideal location with easy access to infrastructure, power, R&D centers for lithium and battery storage, major high-tech population centers and downstream lithium processing facilities.  

The TSB has previously been described as one of the largest lithium provinces in the world and is located approximately 40 kilometers west of Charlotte, North Carolina, United States. The TSB was the most important lithium producing region in the western world prior to the establishment of the brine operations in Chile in the late 1990's. The TSB extends over approximately 60 kilometers in length and reaches a maximum width of approximately 1.6 kilometers.

 The Project was originally explored by Lithium Corporation of America which eventually was acquired by FMC Corporation ("FMC"). FMC and Albemarle Corporation ("Albemarle") both historically mined the lithium bearing spodumene pegmatites from the TSB with the historic Kings Mountain lithium mine being described as one of the richest spodumene deposits in the world by Albemarle. These two mines and their respective metallurgy also formed the basis for the design of the two lithium processing facilities in the region which were the first modern spodumene processing facilities in the western world.
Albemarle and FMC continue to operate these important lithium processing facilities with FMC's Bessemer City lithium processing facility being approximately 14 kilometers from the Project whilst Albemarle's Kings Mountain lithium processing facility is approximately 17 kilometers from the Project.

The Company is in a unique position to leverage its position as a first mover in restarting exploration in this historic lithium producing region with the aim of developing a strategic, U.S. domestic source of lithium to supply the increasing electric vehicle and battery storage markets. For further information, please visit:  www.piedmontlithium.com 
 
ABOUT YOUR PRESENTER: Mr. Anastasios (Taso) Arima. Executive Director Mr. Arima is a resource company executive with a strong history of identifying company-making resource projects. He has extensive experience in the formation and development of resource projects in North America. Mr. Arima is currently Executive Director of Paringa Resources Ltd., which is developing a coal project in the U.S., and formerly Executive Director of Coalspur Mines Ltd.., which is developing a coal project in Canada, and Prairie Mining Ltd., which is developing a coal project in Poland. Mr. Arima was instrumental in the identification and acquisition of all of Paringa’s and Coalspur’s projects, as well as the corporate strategy and marketing of the companies. Mr. Arima began his career as a resources analyst for a Perth based boutique investment banking firm where he specialized in assessing the technical and financial aspects of resource companies and their projects. He has previously worked in the hydrocarbon division at

Worley Parsons Limited. He attended the University of Western Australia where he earned a Bachelor of Commerce and a Bachelor of Engineering. Mr. Arima was appointed a Director of the Company on 1 October 2016.


Nephros presented at  Stock & Bond Club: Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Nephros filters or ultrafilters are used primarily in medical applications in various settings. These ultrafilters are used by dialysis centers for assisting in the added removal of biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and the patients. Additionally, Nephros ultrafilters are used in hospitals and medical clinics for added protection in retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water. These ultrafilters provide barriers that assist in improving infection control with showers, sinks, and ice machines. For more information please visit https://www.nephros.com 

ABOUT YOUR PRESENTER: Daron Evans – President & CEO. Mr. Evans joined the company as President and CEO in April 2015, and has served on Nephros’ board of directors since 2013. He is a life sciences executive with over 20 years of financial leadership and operational experience. Mr. Evans was recently Managing Director of PoC Capital, LLC, and is a member of the board of Zumbro Discovery, Inc., an early stage company developing a novel therapy for resistant hypertension. From 2007 to 2013, Mr. Evans was Chief Financial Officer of Nile Therapeutics, Inc., a development-stage cardiovascular company that merged with Capricor Therapeutics, Inc. (NASDAQ:CAPR) in 2013. From 2004 to 2007, he held various project management and performance improvement roles at Vistakon Inc. and Scios, Inc., both divisions of Johnson & Johnson Corp. Mr. Evans was a co-founder of Applied Neuronal Network Dynamics, Inc. and served as its President from 2002 to 2004. From 1995 to 2002, Mr. Evans served in various roles at consulting firms Arthur D. Little and Booz Allen & Hamilton. Mr. Evans received his Bachelor of Science in Chemical Engineering from Rice University, his Master of Science in Biomedical Engineering from a joint program at the University of Texas at Arlington and Southwestern Medical School and his MBA from the Fuqua School of Business at Duke University.

Dthera Sciences (OTCQB: DTHR) and Sonoma Pharmaceuticals (NASDAQ: SNOA) ​presented n Tuesday, October 17, 2017. About Dthera Sciences: Dthera Sciences, based in San Diego, CA, is a digital therapeutics company focused on developing innovative digital 'quality of life' therapies for neurodegenerative diseases and oncology. The Company's lead product, ReminX, is an artificial-intelligence-powered digital therapeutic designed to reduce anxiety and improve quality of life in patients with Alzheimer's disease and Dementia. For more information, please visit www.dthera.com and www.reminx.com

Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors' and nurses' care, changing patient behavior, and most importantly, reducing cost of care.

Alzheimer's disease is the 6th leading cause of death in the United States. Currently, more than 5 million Americans are living with Alzheimer's disease in the United States alone. In 2017, the direct cost to American society of caring for those with Alzheimer's disease and other dementias will total an estimated $259 billion.

Reminiscence Therapy is an established treatment for Alzheimer's disease that involves reviewing and discussing recognizable memories with patients, typically by looking at photos, and hearing or discussing the familiar stories related to them. Reminiscence Therapy has been in use for nearly 30 years and has proven to be very effective at reducing anxiety and increasing the overall Quality of Life (QoL) in Alzheimer's disease and Dementia patients in numerous clinical trials.

About Sonoma Pharmaceuticals, Inc.Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com 

According to BCC Research, skin conditions are among the most common health problems among most national populations, collectively exceeding the prevalence of conditions such as obesity, hypertension and cancer. The considerable costs of skin diseases include physician visits, hospital care, prescription drugs and over-the-counter products for treating or managing these conditions, as well as indirect costs due to productivity losses.

The global market for skin disease treatment technologies, which reached $17.1 billion in 2015, should reach $20.4 billion in 2020, demonstrating a five-year compound annual growth rate (CAGR) of 3.6%. The U.S market for skin disease treatment, which dominates the global market throughout the period, totaled $7.5 billion in 2015 and should reach $8.6 billion in 2020, reflecting a five-year CAGR of 2.6%.

ABOUT YOUR PRESENTERS: Edward Cox, CEO, Dthera Sciences: Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox served as the President, Director and Secretary of Bio-Quant, Inc. from January 2007 until BioQuant’s merger with NexMed, Inc., which was renamed Apricus Biosciences. Prior to 2007, Mr. Cox previously served as an executive or board member of both public and private companies in the areas of Healthcare, Life Science, Technology and Resources. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Robert Miller, Chief Financial Officer, Sonoma Pharmaceuticals, Inc. Robert Miller has served as our chief financial officer since June 2004 and was a consultant to us from March 2003 to May 2004. Mr. Miller has served as a director of Scanis, Inc. since 1998 and served as acting chief financial officer from 1998 to June 2006. He was a chief financial officer consultant to Evit Labs from June 2003 to December 2004, Wildlife International Network from October 2002 to December 2005, Endoscopic Technologies from November 2002 to March 2004, Biolog from January 2000 to December 2002 and Webware from August 2000 to August 2002. Prior to this, Mr. Miller was the chief financial officer for GAF Corporation, Penwest Ltd. and Bugle Boy and treasurer of Mead Corporation. He received a B.A. in economics from Stanford University and an M.B.A. in finance from Columbia University.Ilan Danieli, CEO has served as Precipio's CEO since founding the company in early 2011. With over 20 years managing small and medium-size companies, some of his previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the US, Canada, Europe and Capital Management, a multi-billion-dollar hedge fund; and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar-Ilan University in Israel.


Aethlon Medical Inc. (NASDAQ: AEMD) presented at The South Florida Stock & Bond Club on Wednesday, June 28, 2017.
Aethlon Medical creates immunotherapeutic medical technologies to address unmet needs in global health and biodefense to combat infectious disease and cancer. The Aethlon Hemopurifier® is a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. The device has been validated to capture Ebola, Zika, Lassa, MERS-CoV, HIV, Hepatitis C, Cytomegalovirus, Epstein-Barr, Herpes Simplex, Chikungunya, Dengue, West Nile, Smallpox related viruses, H1N1 Swine Flu, H5N1 Bird Flu, and the reconstructed Spanish flu virus of 1918. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.

Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). ESI's TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals. Note: Of the hundreds of viruses that are infectious to humans, only 9 are addressed with an approved antiviral drug agent. Compounding this therapeutic challenge are the three to four new viruses that are discovered to be infectious to humans each year. To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."

RECENT DEVELOPMENTS:
Concluded an FDA-approved feasibility study to advance the Hemopurifier® as a broad-spectrum countermeasure against bioterror and pandemic threat viruses. The Company disclosed plans to submit an Expedited Access Pathway (EAP) program application to the FDA. The Company announced that its Exosome Sciences diagnostic subsidiary will conduct a follow-on study related to Chronic Traumatic Encephalopathy (CTE) in former NFL players.

ABOUT YOUR PRESENTER: James A. Joyce, Chairman and Chief Executive Officer. James A. Joyce founded Aethlon Medical in May 1998, and presently serves as Chairman, President and Chief Executive Officer. During Mr. Joyce's tenure, Aethlon has evolved the concept of a medical device to treat infectious disease into a reality of treating infected patients in a clinical trial environment. The resulting Hemopurifier® technology is positioned to treat global pandemic issues such as HIV/AIDS, Hepatitis-C, and pathogens most likely to be weaponized for use in bioterrorism. Mr. Joyce has been an active participant in the emerging biodefense industry. He has testified before Congress on issues related to Project BioShield legislation and the deployment of the Hemopurifier as a countermeasure against biological weapons. His efforts have been instrumental in expanding the definition of treatment countermeasure in Project BioShield legislation to include medical devices. Mr. Joyce recently served on the Project BioShield panel at the Federal Biodefense Research Conference, and was named Co-Chairman of the Bioterrorism/Chemical and Nuclear Security Task Force of the Homeland Security Industries Association. Mr. Joyce actively discusses issues related to infectious disease at various conferences, and has been featured in news stories on CNN, NBC, ABC, and other media outlets. From February 1993 until founding Aethlon Medical, Mr. Joyce was Chief Executive Officer of James Joyce & Associates. Previously, he was founder and Chief Executive Officer of Mission Labs, Inc., was a principal at London Zurich Securities, Inc., and played professional football for the Denver Broncos of the National Football League. Mr. Joyce is a graduate of the University of Maryland.​


The Geo Group (NYSE: GEO) presented on Thursday, June 22, 2017 at The Boca Raton Country Club!
COMPANY OVERVIEW: The GEO Group, Inc. (NYSE: GEO) is the first fully integrated equity real estate investment trust specializing in the design, financing, development, and operation of correctional, detention, and community reentry facilities around the globe. GEO is the world's leading provider of diversified correctional, detention, community reentry, and electronic monitoring services to government agencies worldwide with operations in the
United States, Australia, South Africa, and the United Kingdom. GEO's worldwide operations include the ownership and/or management of 143 facilities totaling approximately 100,000 beds, including projects under development, with a growing workforce of approximately 23,500 professionals. FIRST QUARTER 2017 HIGHLIGHTS: GEO reported total revenues for the first quarter 2017 of $550.6 million up from $510.2 million for the first quarter 2016. Net Income Attributable to GEO of $0.35 per Diluted Share. Adjusted Net Income of $0.37 per Diluted Share. Net Operating Income of $142.4 million. Normalized FFO of $0.51 per Diluted Share. AFFO of $0.65 per Diluted Share. 

ABOUT YOUR PRESENTER: Pablo E. Paez, Vice President, Corporate Relations . Mr. Paez joined GEO 14 years ago and has headed GEO’s Investor Relations department since. He has been involved in heading their investor relations and communications functions in connection with every major equity offering, financing transaction, acquisition, and other corporate actions since 2003. This includes three follow on equity offerings, close to a dozen debt financing or refinancing transactions, six major company acquisitions in addition to smaller asset purchases, and GEO's REIT conversion in 2012/2013. As Vice President of Corporate Relations, since 2010, he oversees all of GEO's investor relations and outside communications functions including media and public relations. He is the primary point of contact at GEO for the Buy Side and Sell Side. He also serves as GEO's private charitable foundation's Executive Director and as Chairman of GEO's Political Action Committee. Mr. Paez holds Bachelors (majoring in Finance) and MBA degrees from Florida Atlantic University (FAU) and currently serves as Chairman of the FAU Alumni Association Board of Directors. He has resided in Palm Beach County since 1999.


The South Florida Stock & Bond Club Proudly Presents:
Legacy Education Alliance Inc., (OTCQB: LEAI) at the Boca Raton Country Club on Tuesday, March 21, 2017.

COMPANY OVERVIEW: Legacy Education Alliance is a leading provider of practical, high-quality, and value-based educational training on the topics of personal finance, entrepreneurship, real estate and financial markets investing strategies and techniques. Their programs are offered through a variety of formats and channels, including free-preview workshops, basic training classes, symposiums, telephone mentoring, one-on-one mentoring, coaching and e-learning, primarily under the Rich Dad® Education brand (“Rich Dad”) which was created in 2006 under license from entities affiliated with Robert Kiyosaki, whose teachings and philosophies are detailed in the book titled, Rich Dad Poor Dad. In addition to Rich Dad, Legacy markets their products and services under a variety of brands, including The Independent Woman, Women in Wealth, Brick Buy Brick - Martin Roberts and Elite Business Star. Their products and services are offered in the United States, Canada, the United Kingdom, and other international markets. Legacy Education Alliance is a global company, with approximately 200 employees, founded in 1996, and through a reverse merger, became a publicly-held company in November 2014. The Company has cumulatively served more than two million students from more than 150 countries and territories over the course of our operating history. Recent highlights for the company include:

Q3 2016 revenue of $22.5 million, with net-income of $1.2 million or $.05 per basic and diluted common share Revenue of $69M for 9 Months ended Sept. 30, 2016 vs $67M same period 2015.

Net Income $2.8 million or $0.13 per basic common share for 9 Months ended Sept. 30, 2016 vs net loss of ($2.6) million or ($0.12) per basic and diluted common share for same 2015 period Strong Cash position with minimal debt. LEAI trades at a discount to other publicly-traded ​companies in education industry. Strong Management Team and Board of Directors/Significant growth opportunities globally.

ABOUT YOUR PRESENTER: CHRISTIAN BAEZA
Executive Vice President and Chief Financial Officer.
Mr. Baeza joined Legacy Education Alliance in April 2015. Prior to joining the company, Mr. Baeza held various senior finance positions including Director of Financial Reporting and Assistant Corporate Controller at Kraton Performance Polymers, Inc. From 2003 to 2008 he held various finance positions at Spectra Energy Corporation. Mr. Baeza began his career as a member of the accounting and auditing practice at Arthur Andersen LLP from 1995 to 1998. Mr. Baeza earned his B.B.A. degree in accounting from Florida International University.

OpGen, Inc., (NASDAQ: OPGN) at the Boca Raton Country Club
​on Wednesday, February 15, 2017 

___________________________________________

COMPANY OVERVIEW: Complete Solutions for Microbial Genetic Analysis - OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. OpGen is dedicated to positively influencing individual healthcare outcomes, enhancing public health, and advancing scientific research by delivering precise, actionable information and results. We offer comprehensive multi-parameter screening and surveillance panels to combat current and emerging multi-drug resistant organisms (MDRO) including carbapenem resistant enterobacteriaceae (CRE) with the next generation of diagnostic and epidemiologic solutions. Learn more at www.opgen.com. OpGen, Acuitas MDRO, Acuitas Lighthouse and QuickFISH are registered trademarks of OpGen, Inc.

ABOUT YOUR PRESENTER: Timothy Dec, CFO. Mr. Dec, has more than 20 years of public company financial leadership experience in technology and healthcare companies. He has served in chief financial officer or other senior financial executive roles at companies in a number of industries, including three publicly traded companies listed on NASDAQ or AMEX, such as Corvis Corporation, and at private equity-backed companies. Prior to joining OpGen, Mr. Dec served as Senior Vice President and Chief Financial Officer for Clubwidesports, LLC, a start-up sports management software company, from January 2014 to April 2015. From August 2007 to December 2012, he was Senior Vice President and Chief Financial Officer of Fortress International Group, Inc., a publicly traded company. Mr. Dec also has public accounting firm experience. He is an adjunct professor at Mount St. Mary’s University in Emmitsburg, Maryland, where he teaches M.B.A. courses in Finance. Mr. Dec holds a B.S. in accounting from Mount Saint Mary’s University, and an M.B.A. from American University in Washington, DC.

________________________________________________

OWC Pharmaceuticals Research Corp. (OTCQB: OWCP) presented
at the Boca Raton Country Club on Wednesday, February 1, 2017

COMPANY OVERVIEW: OWC Pharmaceutical Research Corp. [OTCQB: OWCP] is engaged in the business, through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development of cannabis-based products and treatments specifically designed for Multiple Myeloma, Psoriasis, Fibromyalgia, PTSD, Migraines, and unique delivery systems. These include a Cannabis Sublingual Tablet and a Cannabis Based Psoriasis Topical Cream.

ABOUT YOUR PRESENTER:
Ziv Turner, VP Sales and Business Development OWC Pharmaceutical Research Corp and Managing Director of One World Cannabis Ltd. Mr. Turner is a proven entrepreneur with extensive business development expertise, as well as significant experience within the international business community. A successful engineer, Mr. Turner has 20 years’ experience working in senior management positions for leading telecom companies.

Beginning 1995, he was head of sales for various leaders in the telecommunication industry. His responsibilities included establishing turnkey operating profit centers with regional partners, negotiating with local governments in the APAC countries, establishing OEM, and other partnerships with global integrators and distributors, and implementing regional sales and training programs. Mr. Turner is also the founder of Vocavu, an internet content company.


The South Florida Stock & Bond Club Proudly Presents Precipio Inc. (NASDAQ: PRPO) at the Boca Raton Country Club on
Tuesday, September 19, 2017. Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information on Precipio Inc., please visit www.precipiodx.com

Recent Developments:
Aug 23, 2017 - Precipio, Inc. Prices $6,000,000 Public Offering
Jul 24, 2017 - Precipio Announces Commencement of a Multi-Party Study
to Demonstrate the Impact of Academic Pathology Expertise
on Diagnostic Accuracy
Jul 11, 2017 - Precipio, Inc. (Nasdaq: PRPO) to Ring The Nasdaq Stock Market Opening Bell
Jul 05, 2017 - Precipio Announces Agreement with Clearbridge Health for Liquid Biopsy and Diagnostic Services in Asia
Jun 30, 2017 - Precipio Diagnostics and Transgenomic Complete Merger
Jun 16, 2017 - Precipio and Transgenomic Announce Experts from Yale and Harvard Joining New Scientific Advisory Board to Support Merged Company’s Growth Initiatives
Apr 20, 2017 - Precipio Renews its Exclusive Agreement with Yale School of Medicine for an Additional Five Years

ABOUT YOUR PRESENTER:
Ilan Danieli, CEO has served as Precipio's CEO since founding the company in early 2011. With over 20 years managing small and medium-size companies, some of his previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the US, Canada, Europe and Capital Management, a multi-billion-dollar hedge fund; and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar-Ilan University in Israel.



The South Florida Stock & Bond Club Proudly Presents Piedmont Lithium Ltd (ASX-PLL, NASDAQ-INTERNATIONAL-PLLLY) at the Boca Raton Country Club on 
Thursday, November 30, 2017


About Piedmont Lithium Limited: 

Piedmont Lithium Ltd (ASX-PLL, NASDAQ-INTERNATIONAL-PLLLY) holds a 100% interest in the Piedmont Lithium Project ("Project") which is located within the world-class Carolina Tin-Spodumene Belt ("TSB"), and along trend to the Hallman Beam and Kings Mountain mines, historically providing most of the western world's lithium between 1950 and 1990. The TSB is one of the premier localities in the world to be exploring for lithium pegmatites given its history of lithium bearing spodumene mining, favorable geology and ideal location with easy access to infrastructure, power, R&D centers for lithium and battery storage, major high-tech population centers and downstream lithium processing facilities.  

The TSB has previously been described as one of the largest lithium provinces in the world and is located approximately 40 kilometers west of Charlotte, North Carolina, United States. The TSB was the most important lithium producing region in the western world prior to the establishment of the brine operations in Chile in the late 1990's. The TSB extends over approximately 60 kilometers in length and reaches a maximum width of approximately 1.6 kilometers.

 The Project was originally explored by Lithium Corporation of America which eventually was acquired by FMC Corporation ("FMC"). FMC and Albemarle Corporation ("Albemarle") both historically mined the lithium bearing spodumene pegmatites from the TSB with the historic Kings Mountain lithium mine being described as one of the richest spodumene deposits in the world by Albemarle. These two mines and their respective metallurgy also formed the basis for the design of the two lithium processing facilities in the region which were the first modern spodumene processing facilities in the western world.
Albemarle and FMC continue to operate these important lithium processing facilities with FMC's Bessemer City lithium processing facility being approximately 14 kilometers from the Project whilst Albemarle's Kings Mountain lithium processing facility is approximately 17 kilometers from the Project.

The Company is in a unique position to leverage its position as a first mover in restarting exploration in this historic lithium producing region with the aim of developing a strategic, U.S. domestic source of lithium to supply the increasing electric vehicle and battery storage markets. For further information, please visit:  www.piedmontlithium.com 
 
ABOUT YOUR PRESENTER: Mr. Anastasios (Taso) Arima. Executive Director Mr. Arima is a resource company executive with a strong history of identifying company-making resource projects. He has extensive experience in the formation and development of resource projects in North America. Mr. Arima is currently Executive Director of Paringa Resources Ltd., which is developing a coal project in the U.S., and formerly Executive Director of Coalspur Mines Ltd.., which is developing a coal project in Canada, and Prairie Mining Ltd., which is developing a coal project in Poland. Mr. Arima was instrumental in the identification and acquisition of all of Paringa’s and Coalspur’s projects, as well as the corporate strategy and marketing of the companies. Mr. Arima began his career as a resources analyst for a Perth based boutique investment banking firm where he specialized in assessing the technical and financial aspects of resource companies and their projects. He has previously worked in the hydrocarbon division at

Worley Parsons Limited. He attended the University of Western Australia where he earned a Bachelor of Commerce and a Bachelor of Engineering. Mr. Arima was appointed a Director of the Company on 1 October 2016.


​​​

Please RSVP to Scott Gordon at this e-mail, scottg@corprominence.com